Belotecan

Belotecan
Clinical data
ATC code	L01CE04 (WHO) ;
Identifiers
	IUPAC name (4S)-4-Ethyl-4-hydroxy-11-[2-(isopropylamino)ethyl]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;
CAS Number	256411-32-2;
PubChem CID	6456014;
DrugBank	DB12459 ;
ChemSpider	4958253 ;
UNII	27Z82M2G1N;
KEGG	D03225;
ChEMBL	ChEMBL2107315;
CompTox Dashboard (EPA)	DTXSID60180332 ;
Chemical and physical data
Formula	C25H27N3O4
Molar mass	433.508 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CCNC(C)C)cccc5;
	InChI InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3/t25-/m0/s1 ; Key:LNHWXBUNXOXMRL-VWLOTQADSA-N ;
	(verify)

Belotecan is a drug used in chemotherapy. It is a semi-synthetic camptothecin analogue indicated for small-cell lung cancer and ovarian cancer, approved in South Korea under the trade name Camtobell, presented in 2 mg vials for injection.^[1] The drug has been marketed by Chong Kun Dang Pharmaceuticals^[2] since 2003.^[3]